Relationship Between Natural Killer Cells’ Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
Sponsors and Collaborators
Cancer and Leukemia Group B
National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00896701
Sherif S. Farag, MD, PhD
Indiana University Melvin and Bren Simon Cancer Center
Next post in Leukemia Clinical Trials
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Want to read more?
Please login or register first to view this content.